非NMDA谷氨酸受体拮抗剂GYKI 52466可对抗NMDA拮抗剂地佐环平诱导的运动刺激和抗僵住活性。
The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine.
作者信息
Hauber W, Andersen R
机构信息
Biologisches Institut, Abteilung Tierphysiologie, Universität Stuttgart, Germany.
出版信息
Naunyn Schmiedebergs Arch Pharmacol. 1993 Nov;348(5):486-90. doi: 10.1007/BF00173207.
The effects of the non-NMDA glutamate receptor antagonist GYKI 52466 (2.4 and 4.8 mg/kg, i.p.) on spontaneous locomotor activity and haloperidol-induced catalepsy (0.5 mg/kg, i.p.) were assessed in naive rats and in rats pretreated with the NMDA antagonist dizocilpine (0.08 mg/kg, i.p.). GYKI 52466 given alone did not alter locomotor activity and haloperidol-induced catalepsy, but significantly antagonized the dizocilpine-induced locomotor stimulation and counteracted the anti-cataleptic effects of dizocilpine on haloperidol-induced catalepsy. Thus blockade of non-NMDA glutamate receptors antagonized the behavioural stimulant effects of a NMDA receptor blockade.
在未用药的大鼠以及用NMDA拮抗剂地佐环平（腹腔注射0.08mg/kg）预处理过的大鼠中，评估了非NMDA谷氨酸受体拮抗剂GYKI 52466（腹腔注射2.4和4.8mg/kg）对自发运动活性以及氟哌啶醇诱导的僵住症（腹腔注射0.5mg/kg）的影响。单独给予GYKI 52466不会改变运动活性以及氟哌啶醇诱导的僵住症，但能显著拮抗地佐环平诱导的运动兴奋，并抵消地佐环平对氟哌啶醇诱导僵住症的抗僵住症作用。因此，非NMDA谷氨酸受体的阻断拮抗了NMDA受体阻断的行为兴奋作用。
Zotero 插件